Herantis Pharma Oyj (HEL:HRTIS)

Market Cap	41.82M +24.4%
Revenue (ttm)	n/a
Net Income	-6.62M
EPS	-0.28
Shares Out	26.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,140
Average Volume	27,051
Open	1.580
Previous Close	1.578
Day's Range	1.580 - 1.746
52-Week Range	1.200 - 3.870
Beta	0.59
RSI	24.83
Earnings Date	Aug 20, 2026

About Herantis Pharma Oyj

Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson’s disease (PD). The company’s lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. The company was incorporated in 2008 and is based in Espoo, Finland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 13
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: HRTIS